2009 Influenza A(H1N1) seroconversion rates and risk factors among distinct adult cohorts in Singapore by Chen, M.I.C. et al.
ORIGINAL CONTRIBUTION
2009 Influenza A(H1N1) Seroconversion Rates
and Risk Factors Among Distinct
Adult Cohorts in Singapore
Mark I. C. Chen, PhD
Vernon J. M. Lee, MBBS
Wei-Yen Lim, MBBS
Ian G. Barr, PhD
Raymond T. P. Lin, MBBS
Gerald C. H. Koh, MBBS
Jonathan Yap, MBBS
Lin Cui, PhD
Alex R. Cook, PhD
Karen Laurie, PhD
Linda W. L. Tan, BSc




Vincent T. K. Chow, PhD
Anne Kelso, PhD
Kee Seng Chia, MBBS
Yee Sin Leo, MBBS
ON APRIL 24, 2009, THEWorld Health Organiza-tion (WHO) reported theemergence of a novel in-
fluenza A virus (2009 influenza
A[H1N1]).1 Early data from Mexico
based on laboratory-confirmed cases
suggested higher infection rates in
younger age groups but higher case-
fatality ratios in elderly individuals,2 al-
though it was initially unclear whether
these observations were affected by bi-
ases in case ascertainment. Various ex-
perts have called for serological inves-
tigations tomore accurately determine
infection rates, especially since a sub-
stantial proportion of influenza infec-
tions are asymptomatic.3
Singapore, a Southeast Asian tropical
city-state of 4.8 million people and a
global travel hub, detected its first im-
ported cases of 2009 influenzaA(H1N1)
in late May 2009. Virological surveil-
lance documented sustained commu-
nity transmission from the latter half of
June 2009,4-7 followed by a single epi-
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Context Singapore experienced a single epidemic wave of 2009 influenza A(H1N1)
with epidemic activity starting in late June 2009 and peaking in early August before
subsiding within a month.
Objective To compare the risk and factors associated with H1N1 seroconversion in
different adult cohorts.
Design, Setting, and Participants A study with serial serological samples from 4
distinct cohorts: general population (n=838), military personnel (n=1213), staff from
an acute care hospital (n=558), and staff as well as residents from long-term care fa-
cilities (n=300) from June 22, 2009, to October 15, 2009. Hemagglutination inhibi-
tion results of serum samples taken before, during, and after the epidemic and data
from symptom questionnaires are presented.
Main OutcomeMeasures A 4-fold or greater increase in titer between any of the
3 serological samples was defined as evidence of H1N1 seroconversion.
Results Baseline titers of 40 or more were observed in 22 members (2.6%; 95%
confidence interval [CI], 1.7%-3.9%) of the community, 114military personnel (9.4%;
95% CI, 7.9%-11.2%), 37 hospital staff (6.6%; 95% CI, 4.8%-9.0%), and 20 par-
ticipants from long-term care facilities (6.7%; 95% CI, 4.4%-10.1%). In participants
with 1 or more follow-up serum samples, 312 military personnel (29.4%; 95% CI,
26.8%-32.2%) seroconverted compared with 98 community members (13.5%; 95%
CI, 11.2%-16.2%), 35 hospital staff (6.5%; 95% CI, 4.7%-8.9%), and only 3 long-
term care participants (1.2%; 95% CI, 0.4%-3.5%). Increased frequency of serocon-
version was observed for community participants from households in which 1 other
member seroconverted (adjusted odds ratio [OR], 3.32; 95%CI, 1.50-7.33), whereas
older age was associated with reduced odds of seroconversion (adjusted OR, 0.77 per
10 years; 95% CI, 0.64-0.93). Higher baseline titers were associated with decreased
frequency of seroconversion in community (adjusted OR for every doubling of base-
line titer, 0.48; 95% CI, 0.27-0.85), military (adjusted OR, 0.71; 95% CI, 0.61-0.81),
and hospital staff cohorts (adjusted OR, 0.50; 95% CI, 0.26-0.93).
Conclusion Following the June-September 2009 wave of 2009 influenza A(H1N1),
13% of the community participants seroconverted, and most of the adult population
likely remained susceptible.
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demic wave peaking in the first week of
August and subsiding by September
2009.7,8We initiateda cohort studyusing
serial blood specimens to determine an-
tibody levels against 2009 influenza
A(H1N1) as a marker of infection in 3
different population groups of public
health concern—military personnel,
acute care hospital workers, and staff
members and residents of long-termcare
facilities and compared themwith com-
munity-dwellingadults.The studyaimed
to compare the risk of infection in these




This was a cohort study including 4 dif-
ferent populations in Singapore and in-
volving the planned collection of up to
3 serial serological samples fromeach in-
dividual: a baseline sample was col-
lected either before the local 2009 influ-
enza A(H1N1) epidemic using banked
samples or in the early epidemic phase
beforewidespread community transmis-
sion; the second sample was collected
during the epidemic about 4 weeks af-
ter the epidemic had peaked; and third
samplewas collected at least 4weeks af-
ter epidemic activity had subsided.
Whenpossible, the start andstopdates
of specimen collection across the co-
hortswere intentionally synchronized to
allow intercohort comparison of sero-
conversion rates at each follow-up time
point. Clinical symptom reviews were
performed using a standardized ques-
tionnaire once every 2 weeks for the
community cohort and at each sample
collection in the other 3 cohorts. Par-
ticipants were asked to report all new-
onset respiratory symptoms and consti-
tutional symptoms such as headaches,
myalgia, and fever (including mea-
sured temperaturewhere available); and
baseline demographic data andwhether
they had ever received seasonal influ-
enza vaccination in the past.
Study Populations
1. Community-dwelling adults were
recruited from theMultiethnic Cohort
(MEC) of the Singapore Consortium of
Cohort Studies (SCCS), a long-term re-
search project initiated to study gene-
environment interactions in chronic
disease causation. The MEC (http:
//www.nus-cme.org.sg/home.html) is a
subcohort of the SCCS, comprising
about 9000 community-dwelling
healthy Singaporeans aged 21 to 75
years, recruited through public out-
reach activities and referrals for which
recruitment is ongoing. We enrolled
newMEC recruits into the study (from
late June 2009), and recontacted 2400
existingMECparticipants, with the aim
of enrolling 900 participants. For the
first serum sample collection, new re-
cruits donated fresh baseline blood,
while existing participants granted per-
mission to use specimens banked on
original recruitment. Symptom ques-
tionnaires were administered via tele-
phone interviews at 2-week intervals.
2. Themilitary personnel cohortwas
recruited from the Singapore Armed
Forces, Singapore’s national military
and composed largely of conscripted
males who serve after completion of
high school from ages 18 through 19
years. Most individuals reside in mili-
tary camps during weekdays but re-
turn to the community on weekends.
Individuals were recruited by invita-
tion from 15 units selected to give a
good representation of the entire mili-
tary structure, with a total personnel
of 1570. Blood samples were taken at
all 3 time points together with self-
administered questionnaires.
3. Hospital staff fromTan Tock Seng
Hospital, an acute care hospital with
6000 staff members, formed the third
cohort. Staff members were recruited
through e-mail notifications and by
word-of-mouth referrals. Blood samples
were taken at all 3 time points along
with self-administered questionnaires.
Information on symptomatic episodes
was augmented through sickness ab-
senteeism records for details such as
dates of illness.
4. Staff and residents from 2 long-
term care facilities, Jamiyah Home for
the Aged and Peacehaven Nursing
Home, were recruited by invitation. Be-
tween the 2 facilities are a total of 179
staff members and 520 residents (200
residentswere able to give consent)who
rarely go outside the facility. In this co-
hort, only the first and third serum
samples were taken, with question-




Venous bloodwas taken in 5- to 10-mL
plain tubes. Serum samples were pre-
treated with receptor destroying en-
zyme (RDE [II], Deka Seiken Co Ltd,
Tokyo, Japan), 1:4 (vol/vol), at 37°C for
16 hours, before enzyme inactivation
by the addition of an equal volume of
1.6% trisodium citrate (Ajax Chemi-
cals, Melbourne, Australia) and incu-
bation at 56°C for 30 minutes.
The hemagglutination inhibition as-
say was performed according to stan-
dard protocols at theWorld Health Or-
ganization Collaborating Centre for
Reference andResearch on Influenza in
Melbourne, Australia.9 Egg-grown
A/California/7/2009 A(H1N1) pan-
demic viruswas purified by sucrose gra-
dient, concentrated and inactivatedwith
-propiolactone, to create an influ-
enza zonal pool preparation (a gift from
CSL Limited, Melbourne, Australia).
Twenty-five microliters (4 hemagglu-
tination units) of influenza zonal pool-
A/California/7/2009 virus was incu-
bated at room temperature with an
equal volumeof RDE-treated serum. Se-
rum samples were titrated in 2-fold di-
lutions in phosphate-buffered saline
from 1:10 to 1:1280. Following 1 hour
of incubation, 25 µLof 1% (vol/vol) tur-
key red blood cells was added to each
well. Hemagglutination inhibition was
read after 30 minutes. Titers were ex-
pressed as the reciprocal of the high-
est dilution of serumwhere hemagglu-
tination was prevented. We defined
seroconversion as a 4-fold or greater in-
crease in antibody titers.
The hemagglutination inhibition as-
saywasassessedonpairedserumsamples
from56casesof2009influenzaA(H1N1)
that were confirmed through reverse
transcription–polymerase chain reac-
tion(RT-PCR):28participants fromthis
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cohort study, plus 7 outbreak-related
cases and 21 clinical cases admitted to
Tan Tock Seng Hospital. Forty-five
patients (80%)seroconverted to thepan-
demic strain,A/California/7/2009.Only
20 patients (20%) seroconverted to
A/Brisbane/59/2007(H1N1)and7(13%),
to A/Wisconsin/15/2009(H3N2).
Data Analysis and Statistics
Participants who seroconverted be-
tween any successive pairs of blood
specimens (either from baseline to the
second sample, second to third sample,
or first to third sample) were consid-
ered as ever having had serological evi-
dence of infection during the study pe-
riod. Geometric mean titers (GMTs)
were estimated by assigning a value of
5 for titers lower than 10 and a value
of 1280 for titers of 1280 or higher.
Episodes of acute respiratory illness
were defined as new-onset illness with
any respiratory symptoms of rhinor-
rhea, nasal congestion, sore throat, or
cough; and febrile respiratory illnesswas
defined as an acute respiratory episode
with self-reported fever or a body tem-
perature of 37.5°C or higher. The date
of each illness episode was the earliest
symptom onset date or sickness absen-
teeism if onset dates were unavailable.
Febrile respiratory illness episodes that
preceded seroconversion were graphed
by illness date against influenza epi-
demic activity. Likewise, illness epi-
sodes preceding seroconversion were
used to estimate the proportion of sero-
converting individualswith acute respi-
ratory or febrile respiratory illness epi-
sodes. Singapore influenza epidemic
activity data were from laboratory sur-
veillance on theweekly proportionof in-
fluenza-like illness general practice
samples testing positive for 2009 influ-
enza A(H1N1) and the weekly number
of influenza-like illness consults seen by
a separate sentinel general practice net-
work7,8—the 2 data sets were multi-
plied to give a weekly epidemic curve.
As some participants formed natu-
ral groupings, such as households and
military units, and as contagious dis-
ease status is nonindependent within
groups, we accounted for nonindepen-
dence using dummy variables corre-
sponding to disease status of others
within the group. For the community
cohort, we introduced 2 indicator vari-
ables coding for 3 categories corre-
sponding to known seroconversion
status for other individuals in the
household—at least 1 other house-
hold member seroconverted, no one
else in the household seroconverted, or
other permutations (no other house-
hold member in the study or other
members in the study but seroconver-
sion not known). For military camps,
a variable indicating the proportion of
the other unit members who serocon-
verted was introduced. The same was
done for hospital staff, using func-
tional operating units (75 wards or
departments). We then performed
Table 1. Cohort Characteristics
Community Military Hospital Staff Long-term Care
Timing of blood draws in 2009
Baseline June 22-27a June 22-July 1 June 22-July 7 July 17-27
Second August 20-29 August 20-September 3b August 19-September 3 NA
Third October 6-11 September 29-October 9 September 29-October 15 October 5-7
Samples, No. (%) of participants
Baseline 838 (100) 1213 (100) 558 (100) 300 (100)
Second 621 (74) 920 (76) 501 (90) NA
Third 689 (82) 776 (64) 467 (84) 250 (83)
All 3 samples 583 (70) 636 (52) 431 (77) NA
2 727 (87) 1060 (87) 537 (96) 250 (83)
No. (%) of reviews completedc 4766 (95) 1680 (69) 1098 (98) 250 (83)
Age, mean (range), y 43 (21-74) 22 (17-62) 34 (20-67) 56 (18-109)
Age in years, No. (%)
15-19 0 554 (46) 0 12 (4)
20-24 92 (11) 473 (39) 110 (20) 28 (9)
25-29 66 (8) 93 (8) 129 (23) 24 (8)
30-39 152 (18) 44 (4) 164 (29) 47 (16)
40-49 298 (36) 31 (3) 96 (17) 14 (5)
50-59 166 (20) 14 (1) 52 (9) 32 (11)
60 64 (8) 4 (1) 7 (1) 143 (48)
Sex, No. (%)
Male 353 (42) 1175 (97) 92 (16) 131 (44)
Female 485 (58) 38 (3) 466 (84) 169 (56)
Seasonal influenza vaccine, No. (%)
No 729 (87) 696 (57) 52 (9) 160 (53)
Yes 109 (13) 517 (43) 506 (91) 140 (47)
Abbreviation: NA, not applicable.
aSpecimen collection dates for 23 community cohort participants; baseline samples for the remaining 815 participants used specimens banked on original recruitment into ongoing
research study on chronic disease causation.
bExcludes 11 samples taken on September 9 and 10, 2009.
cDenominator is based on baseline multiplied by number of scheduled follow-up reviews: 6 for community, 2 for military, 2 for hospital staff, 1 for long-term care.
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univariate andmultivariate logistic re-
gression using these dummy variables
alongside baseline titer, age, sex, and
seasonal influenza vaccine status to as-
sess their contribution to seroconver-
sion; odds ratios (ORs) with asymp-
totic Wald 95% confidence intervals
(CIs) and 2-sidedP values are presented
with statistical significance set at the .05
level.10 Multivariate analysis involved
stepwise logistic regression, wherein
variables that did not improve model
fit at P .10 were discarded.
A sample size of 450 participants per
cohort was needed to give a power of
90% to detect (with a 2-sided P value
of.05) seroconversion rates thatwere
10% higher for a given cohort than the
community sample, which was as-
sumedwould have seroconversion rates
of 20% to 30% (similar to the 1957 pan-
demic11). Target sample sizes were 600
for hospital staff and long-term care fa-
cility cohorts and 900 for the commu-
nity cohort to allow for loss to fol-
low-up rates of 25% and 50%,
respectively. The military cohort was
substantially larger to allow compari-
son of seroconversion rates in differ-
ent military units.
Where appropriate, 95%CIs for pro-
portionswere computed using theWil-
son score-based method.12,13 All statis-
tical analyses were performed using
STATA 10.0 (StataCorp, College Park,
Texas).
Ethics Review
Written informed consent was ob-
tained from all participants. The study
was approved by the ethics review
boards of the National Healthcare
Group, Singapore Armed Forces, and
National University of Singapore.
RESULTS
TABLE 1 describes the 4 cohorts. We
completed baseline collection from838
community participants by June 27,
2009, 1213military participants by July
1, 2009, and 558 hospital participants
by July 7, 2009, after simultaneously
starting recruitment on June 22, 2009.
The community cohort–banked
samples dated back to June 2005, with
790 of 838 specimens (94%) collected
beforeMay 26, 2009, when the first im-
ported influenza 2009 A(H1N1) case
was detected in Singapore.4 Logistical
difficulties delayed baseline collection
of the 300 long-term care facilities co-
hort participants until July 27, 2009, but
there were no confirmed cases or ex-
cess influenza-like illness in either long-
term care facility before the collection
date. All participants (except those from
the long-term care facilities cohort)
were recalled for the second sample col-
lection between August 19 and Sep-
tember 3, 2009, and the third sample
collection between September 29 and
October 15, 2009. In each cohort, 80%
Table 2. Baseline Titers by Cohorts, by Seasonal Influenza Vaccination in All Cohorts, and by Age Groups in the Community Cohort
No. of
Participants
Distribution of Antibody Titers, No. (%)
GMT (95% CI) P Value10a 10-20 40
Cohort
Community 838 738 (88) 78 (9) 22 (3) 5.8 (5.6-6.0)
Military 1213 921 (76) 178 (15) 114 (9) 7.4 (7.1-7.7) .001b
Hospital staff 558 351 (63) 170 (30) 37 (7) 7.6 (7.2-8.1) .001b
Long-term care facilities 300 252 (84) 28 (9) 20 (7) 6.4 (6.0-6.9) .007b
Seasonal influenza vaccine
Community
No 756 666 (88) 73 (10) 17 (2) 5.8 (5.6-6.0)
.34c
Yes 82 72 (88) 5 (6) 5 (6) 6.1 (5.3-7.1)
Military personnel
No 696 538 (77) 91 (13) 67 (10) 7.4 (6.9-7.9)
.98c
Yes 517 383 (74) 87 (17) 47 (9) 7.4 (6.9-7.9)
Hospital staff
No 52 39 (75) 11 (21) 2 (4) 6.4 (5.6-7.4)
.07c
Yes 506 312 (62) 159 (31) 35 (7) 7.8 (7.3-8.3)
Long-term care facilities
No 160 141 (88) 9 (6) 10 (6) 6.1 (5.5-6.7)
.14c
Yes 140 111 (79) 19 (14) 10 (7) 6.8 (6.1-7.7)
Age groups in community cohort, y
20-24 92 73 (79) 14 (15) 5 (5) 6.7 (5.8-7.7)
25-29 66 53 (80) 10 (15) 3 (5) 6.6 (5.6-7.7)
30-39 152 136 (89) 14 (9) 2 (1) 5.6 (5.3-6.0)
.002d
40-49 298 270 (91) 20 (7) 8 (3) 5.7 (5.4-6.0)
50-59 166 148 (89) 15 (9) 3 (2) 5.7 (5.3-6.1)
60 64 58 (91) 5 (8) 1 (2) 5.5 (5.0-6.1)
Abbreviations: CI, confidence interval, GMT, geometric mean antibody titers.
aNo detectable antibodies.
bCompared with community cohort using unpaired t test.
cParticipants who did not have seasonal influenza vaccine compared with those who did using unpaired t test.
dUsing linear regression with age as an explanatory value for GMT.
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or more returned for at least 1 fol-
low-up sample so that, except for the
long-term care facilities cohort, the fi-
nal number of participants for which
seroconversion data was available ex-
ceeded our targeted sample sizes.
Scheduled follow-up symptom re-
viewswere also reasonably complete ex-
cept in the military for which fol-
low-up reviewswere restricted to those
with follow-up blood samples.
Military personnel were a mean age
of 22 years (range, 17-62 years); hos-
pital staff, 34 years (range, 20-67 years);
and the community cohort, 43 years
(range, 21-74 years), whereas the long-
term care cohort, of which 54% (162/
300) were residents, were a mean age
of 56 years (range, 18-109 years). Sex
distributions reflect the predomi-
nantly male workforce in the military
(97%, 1175/1213) and female work-
force in the hospital staff (84%, 466/
558). Only 13% (109/838) in the com-
munity cohort had previously ever
received seasonal influenza vaccine
compared with 91% (506/558) of hos-
pital staff, 43% (517/1213) of mili-
tary, and 47% (140/300) of partici-
pants from long-term care facilities.
The baseline GMT for hospital staff
was 7.6 (95%CI, 7.2-8.1); military per-
sonnel, 7.4 (95%CI, 7.1-7.7); and staff
and residents of long-term care facili-
ties, 6.4 (95%CI, 6.0-6.9), all of which
were significantly higher than those of
the community cohort: 5.8 (95% CI,
5.6-6.0; TABLE 2). The GMT of in-
hospital staff who had received a sea-
sonal influenza vaccine was 7.8 (95%
CI, 7.3-8.3); whereas the GMT of staff
who had not received the seasonal vac-
cine was 6.4 (95%CI, 5.6-7.4; P=.07).
In the largely unvaccinated commu-
nity cohort, younger age was signifi-
cantly associated with higher baseline
titers (P=.002).
The FIGURE shows that the epi-
demic curve peak for the community
cohort coincidedwith the national peak
in influenza epidemic activity, whereas
themilitary personnel epidemic peaked
2 to 3weeks earlier. Seroconversion oc-
curredmostly between the baseline and
the second sample for the community
Figure. Epidemic Curves for Each Cohort Constructed From Febrile Respiratory Illness
































































































































Braces represent the sampling periods and are compared against influenza epidemic activity as observed through
H1N1-2009 general practice sentinel data. The H1N1-2009 general practice sentinel surveillance data are con-
structed by multiplying the proportion of laboratory surveillance isolates that tested positive for H1N1-2009
from the Ministry of Health and the number of influenza-like illness consults per general practice from a sen-
tinel general practice network,7,8 which gives the estimated number of general practice influenza-like illness
consults that are influenza 2009 A(H1N1) for that week. Epidemic activity appears to have peaked in the week
starting on August 2, 2009, at an estimated 15.5 consults per general practice per week.
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with 70 of 98 eventual seroconver-
sions (71%; 95%CI, 62%-79%) and for
themilitary cohorts with 254 of 312 se-
roconversions (81%; 95% CI, 77%-
85%) comparedwith hospital staff with
16 of 35 seroconversions (46%; 95%CI,
30%-62%) (TABLE 3). In the long-
term care facilities cohort, only 3 of 250
(1.2%; 95% CI, 0.4%-3.5%) serocon-
verted, so this cohort was omitted from
additional analysis.
Table 3 also shows the proportions
of those who seroconverted as an in-
dicator of the variation in risk of infec-
tion. In the community cohort, 13% se-
roconverted vs 29% in themilitary and
7% in the hospital staff cohort. Com-
munity participants aged 20 through 24
yearswere at higher risk than older par-
ticipants with 21% of those in commu-
nity and 24% of those in the military
cohorts seroconverting vs 8% of those
60 years or older in the community co-
hort. Furthermore, 44% of those aged
15 through 19 years in the military co-
hort seroconverted. No discernible
effect fromprior seasonal influenza vac-
cination existed except for the mili-
tary cohort, for which 37% of unvac-
cinated participants seroconverted vs
19% of those vaccinated. Participants
with higher baseline titers had lower
seroconversion rates—13% of mili-
tary participants with titers of 40 or
higher seroconverted vs 32% with ti-
ters lower than 10. Seroconversion data
were available for 223 participants re-
siding in the 106 households in the
community cohort. Twenty-nine per-
cent (10/34; 95%CI, 17%-46%)of those
living with another household mem-
ber who was known to have serocon-
verted vs 12% (23/189; 95% CI, 8%-
18%) of those living in households in
which no one else had seroconverted
and 13% (65/504; 95% CI, 10%-16%)
in other community participants for
whom seroconversion data for other
household members were not avail-
able had seroconversion. Because there
was no significant difference in sero-
conversion rates for the latter 2 groups
(P=.79), these were combined during
multivariate analysis.
On multivariate analysis (TABLE 4),
having another householdmemberwho
seroconverted remained associatedwith
Table 3. Factors Associated With Seroconversion by Cohorts
Participants With Seroconversion by Cohort
Community Members Military Personnel Hospital Staff
No./Total % (95% CI) No./Total % (95% CI) No./Total % (95% CI)
Detection of seroconversion by blood draw
Baseline to second blood draw 70/621 11 (9-14) 254/920 28 (25-31) 16/501 3 (2-5)
Second to third 16/584 3 (2-4) 21/636 3 (2-5) 12/432 3 (2-5)
Baseline to third 83/690 12 (10-15) 223/776 29 (26-32) 32/468 7 (5-9)
Ever 98/727 13 (11-16) 312/1060 29 (27-32) 35/537 7 (5-9)
Age, ya
15-19 115/259 44 (38-50)
20-24 16/78 21 (13-31) 96/399 24 (20-28) 6/104 6 (3-12)
25-29 5/50 10 (4-21) 11/75 15 (8-24) 9/123 7 (4-13)
30-39 18/132 14 (9-21) 1/37 3 (0-14) 7/157 4 (2-9)
40-49 43/267 16 (12-21) 0/28 0 (0-12) 10/95 11 (6-18)
50-59 12/147 8 (5-14) 1/11 9 (2-38) 2/51 4 (1-13)
60 4/53 8 (3-18) 1/4 25 (5-70) 1/7 14 (3-51)
Sexa
Male 45/295 15 (12-20) 308/1028 30 (27-33) 5/90 6 (2-12)
Female 53/432 12 (10-16) 4/32 13 (5-28) 30/447 7 (5-9)
Seasonal influenza vaccinea
No 87/659 13 (11-16) 227/616 37 (33-41) 1/50 2 (0-10)
Yes 11/68 16 (9-27) 85/444 19 (16-23) 34/487 7 (5-10)
Baseline titersa
10 93/631 15 (12-18) 252/799 32 (28-35) 27/340 8 (6-11)
10 2/48 4 (1-14) 30/91 33 (24-43) 8/126 6 (3-12)
20 3/27 11 (4-28) 17/71 24 (16-35) 0/36 0 (0-10)
40 0/21 0 (0-15) 13/99 13 (8-21) 0/35 0 (0-10)
Other household membera,b
1 10/34 29 (17-46)
No one else 23/189 12 (8-18)
Other 65/504 13 (10-16)
Abbreviation: CI, confidence interval.
aNumerator is individuals who had ever seroconverted; denominator is individuals who had at least 1 follow-up sample (second, third, or both samples).
bOther household member seroconverted: at least 1 other household member with seroconversion, no one else in household with seroconversion, and other combinations (no
other household member in the study or other members in the study but seroconversion data not available).
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a higher likelihood of infection (ad-
justedOR,3.32; 95%CI, 1.50-7.33).The
proportion within the unit who had se-
roconverted was associated with in-
creased risk of infection in the military
(adjusted OR, 1.42; 95% CI, 1.27-
1.59) but not among hospital staff. Af-
ter adjusting for infections in the same
military unit, vaccination and sex were
no longer significant, but older age re-
mained significantly protective (ad-
justed OR, 0.42 per 10 years; 95% CI,
0.27-0.65), similar to the community co-
hort (adjusted OR, 0.77 per 10 years;
95% CI, 0.64-0.93). Higher baseline ti-
ters had lower likelihood of seroconver-
sion in the community (adjusted OR,
0.48; 95% CI, 0.27-0.85), hospital staff
(adjusted OR, 0.50; 95% CI, 0.26-
0.93), andmilitary cohorts (adjustedOR,
0.71; 95% CI, 0.61-0.81).
During the study period, acute res-
piratory and febrile respiratory illness
episodes were more common for indi-
viduals who seroconverted. In commu-
nity participants, 73% (72/98; 95%CI,
64%-81%) of those who had serocon-
verted reported 1 or more acute respi-
ratory illness episodes vs 43% (269/
629; 95% CI, 39%-47%) of those who
had not (P .001), and 44% (43/98;
95% CI, 34%-54%) of those who had
seroconvertedhad febrile respiratory ill-
ness episodes vs 9% (56/629; 95% CI,
7%-11%) of those who had not
(P .001). Among hospital staff, 69%
(24/35; 95%CI, 52%-81%)of thosewho
had seroconverted had acute respira-
tory illness vs 15% (75/502; 95% CI,
12%-18%) of those who had not
(P .001), and 51% (18/35; 95% CI,
36%-67%) of those who had serocon-
verted had febrile respiratory illness vs
8% (41/502; 95%CI, 6%-11%) of those
who had not (P .001). The military
cohort reported lower acute respira-
tory illness and febrile respiratory ill-
ness rates: 31% (98/312; 95%CI, 27%-
37%) of those who had seroconverted
had acute respiratory illness vs 24%
(181/748; 95% CI, 21%-27%) of those
who had not (P=.02), and 16% (50/
312; 95% CI, 12%-21%) of those who
had seroconverted had febrile respira-
tory illness vs 7% (56/748; 95%CI, 6%-
10%) of those who had not (P .001).
COMMENT
To our knowledge, this is the first co-
hort study designed to estimate the ex-
tent of infection with 2009 influenza
A(H1N1) using serological assays. Our
study shows that at the end of the first
epidemic wave in Singapore a substan-
tial proportion of the Singapore adult
population lack antibodies to the novel
strain, with only 13% of the commu-
nity cohort having serological evi-
dence of infection. This infection rate
estimate is compatible with the 11%
clinical attack rate for Singapore esti-
mated from influenza-like illness re-
porting7 and was fairly similar to esti-
mates of adult incidence from a cross-
sectional serological study conducted
after the first epidemicwave of 2009 in-
fluenza A(H1N1) in the United King-
dom.14
Our study also shows the variation
in infection risks, with younger age
groups and military personnel having
much higher infection rates. The lower
infection rates in older participants
corroborate other epidemiological ob-
servations.14,15 Because therewas no 15-
to 19-year age group in the commu-
nity cohort, we are unable to conclude
whether higher infection rates in the
military were due to the younger age
or increased transmission, althoughhis-
torical pandemic data16 and the strong
association between infection risk and
level of intraunit infections in our study
Table 4. Univariate and Multivariate Analysis for Factors Associated With Seroconversion in Community, Military, and Hospital Staff
Crude OR (95% CI) P Value Adjusted OR (95% CI) P Value
Community
Age per 10 y 0.81 (0.67-0.97) .02 0.77 (0.64-0.93) .007
Female sex 0.78 (0.51-1.19) .25
Had seasonal influenza vaccine 1.27 (0.64-2.51) .50
Baseline titera 0.54 (0.31-0.94) .03 0.48 (0.27-0.85) .01
Other household memberb 2.86 (1.33-6.19) .007 3.32 (1.50-7.33) .003
Military
Age per 10 y 0.25 (0.15-0.41) .001 0.42 (0.27-0.65) .001
Female sex 0.33 (0.12-0.96) .04
Had seasonal influenza vaccine 0.41 (0.30-0.54) .001
Baseline titera 0.76 (0.66-0.87) .001 0.71 (0.61-0.81) .001
Proportion in unit (per 10%)c 1.56 (1.40-1.72) .001 1.42 (1.27-1.59) .001
Hospital
Age per 10 y 1.06 (0.76-1.46) .74
Female sex 1.22 (0.46-3.24) .69
Had seasonal influenza vaccine 3.68 (0.49-27.46) .20
Baseline titera 0.50 (0.26-0.93) .03 0.50 (0.26-0.93) .03
Proportion in unit per 10%c 1.24 (0.83-1.85) .30
Abbreviations: CI, confidence interval; OR, odds ratio.
aFor every unit increase in baseline titer, for which the integer values 0 to 8 denote titers of 10, 10, 20, 40, 80, 160, 320, 640, and 1280 or more, respectively.
bHad at least 1 other household member who seroconverted compared with all other community participants (including those from households for which no one else serocon-
verted, no other household member in the study, or other members in the study but seroconversion data not available).
cProportion in unit who seroconverted.
A(H1N1) SEROCOVERSION RATES IN SINGAPORE
©2010 American Medical Association. All rights reserved. (Reprinted) JAMA, April 14, 2010—Vol 303, No. 14 1389
Downloaded From:  on 08/24/2018
point to greater transmission intensity
in military populations. This suggests
that special preventivemeasures inmili-
tary subpopulationsmay be justified in
the event of influenza epidemics. The
increased risk of infection for commu-
nity participants from households in
which at least 1 other member sero-
convertedwas expected, although itwas
not possible to determine the direc-
tion of transmission in this study.
In contrast, hospital staff and the
long-term care facilities cohorts had
lower infection rates. Besides the high
baseline titers, hospital staff may also
have been protected at work because of
intense patient and visitor screening,
use of personal protective equipment,
and other infection control measures
deployed during the epidemic.17,18 Such
combination strategies may help pre-
vent influenza transmission, although
it is difficult to attribute the specific
effect of these interventions without
control groups. Staff and residents of
the long-term care facilities may like-
wise have been protected by similar
measures, but other factors such as re-
duced host susceptibility in the older
age groups should be considered, for as
others have found, long-term care fa-
cilities were largely spared from 2009
influenza A(H1N1) outbreaks.19 Be-
cause large segments of these popula-
tions lacked antibodies after the initial
epidemic wave, outbreaks might oc-
cur in subsequent epidemic waves.
Likewise, only 13% of the community
cohort seroconverted, which supports
the case for targeted vaccination in
populations for which protection is de-
sired.
In both the community cohort and
hospital staff, about half the partici-
pants who seroconverted reported a fe-
brile respiratory illness episode. This is
comparablewith estimates of influenza-
like illness proportions among sero-
logically confirmed influenza cases from
seasonal influenza studies.20,21 Febrile
respiratory illness episodes were less
common among nonseroconverters,
showing that febrile respiratory ill-
ness is reasonably specific (but not very
sensitive) for influenza during epidem-
ics.22 The large number of community
participants with acute respiratory ill-
ness episodes who did not serocon-
vertmay have had other infections; rhi-
novirus circulates throughout the year
and is the most common identifiable
cause of acute respiratory illness in Sin-
gapore.23,24 There were proportion-
ately fewer febrile respiratory illness epi-
sodes inmilitary personnel possibly due
to underreporting forwhich illness data
were based solely on self-adminis-
tered questionnaires.
Using serological cohorts is one of the
best ways to estimate infection rates,
particularly for large outbreaks such as
2009 influenza A(H1N1) for which
laboratory confirmation cannot be per-
formed formost cases.Our cohort study
demonstrates that those with higher
baseline titers have significantly lower
infection rates, perhaps indicative of
protection against 2009 influenza
A(H1N1) infection.Our study also sug-
gests that baseline circulating antibod-
ies to 2009 influenza A(H1N1) exist in
individuals without clinical evidence of
prior infection (Table 2). Baseline an-
tibody titers were marginally higher in
vaccinated hospital staff, compatible
with findings that 12% to 22% of adults
experienced a 4-fold or greater increase
in antibody titers to 2009 influenza
A(H1N1) after seasonal influenza vac-
cination.25 Our findings on age-specific
prevalence of baseline antibodies are
similar to those fromChinawhere only
1.7% of adults (serum samples col-
lected July-August 2008) had preexist-
ing antibody titers of at least 40 to 2009
influenza A(H1N1) on hemagglutina-
tion inhibition assay, with even lower
responses in those 60 years or older.26
In contrast, Hancock et al25 found that
baseline antibodies were more preva-
lent in older adults in theUnited States,
suggesting that further studies are
needed to understand whether the
discrepant observations are due to
seasonal H1N1 vaccination,26 expo-
sure to influenza, or other community-
specific factors. Notably, in commu-
nity participants aged 65 years or older
(for whom vaccination is recom-
mended), only 11% reported ever hav-
ing received influenza vaccination. This
corroborates previous estimates that in-
fluenza vaccine uptake in Singapore re-
mains low.27
One limitation of our study is the lack
of a pediatric population due to the
difficulty in obtaining serial blood
specimens in this age group; cross-
sectional surveys using residual samples
may be more feasible for estimating
childhood infection rates. Further-
more, our community cohort may not
be truly representative of the Sin-
gapore population because it largely
comprised healthy volunteers. Al-
though these factors preclude us from
determining the actual infection rate in
Singapore, our study allows us to re-
fine estimates on the numbers at risk,
obtain better case fatality rate esti-
mates in adult age groups, and inform
policy on vaccination. Finally, apart
from the community cohort, the base-
line collection started after influenza
2009 A(H1N1) had begun to circu-
late, albeit at low levels. However, sub-
analysis of themilitary and hospital co-
horts found no evidence of higher
baseline titers in participants whose
baseline samples were collected later.
In conclusion, our study showswide
variation in serologically determined in-
fection rates by cohorts and age groups,
suggesting that context-specific risks of
infection need to be taken into ac-
count and that interventions need to be
tailored to the population at risk. Al-
though it appears that a large propor-
tion of the Singapore adult population
remain susceptible to the 2009 influ-
enza A(H1N1) virus after the first epi-
demic wave, for a significant second
wave to occur, a sufficient number of
susceptible children may also be re-
quired for efficient transmission. These
and other factors will need to be con-
sidered in the determination of opti-
mal pandemic vaccination strategies for
influenza A(H1N1).28
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